SOURCE: Izard Nobel LLP

August 11, 2009 17:19 ET

Izard Nobel LLP Announces Class Action Lawsuit Against Repros Therapeutics, Inc.

WEST HARTFORD, CT--(Marketwire - August 11, 2009) - The law firm of Izard Nobel LLP, which has significant experience representing investors in prosecuting claims of securities fraud, announces that a lawsuit seeking class action status has been filed in the United States District Court for the Southern District of Texas on behalf of those who purchased the common stock of Repros Therapeutics, Inc. ("Repros" or the "Company") (NASDAQ: RPRX) between July 1, 2009 and August 3, 2009, inclusive (the "Class Period").

The Complaint charges that Repros and certain of its officers and directors violated federal securities laws by issuing materially false and misleading press releases regarding the success of clinical trials for its drug Proellex. On August 3, 2009, Repros revealed that it was suspending Proellex clinical trials based on a clinically significant increase in liver enzymes among participants. On that day, Repros stock fell to a close of $1.31, a 48% drop from a close of $2.53 on the previous trading day.

If you are a member of the class, you may, no later than October 6, 2009, request that the Court appoint you as lead plaintiff of the class. A lead plaintiff is a class member that acts on behalf of other class members in directing the litigation. Although your ability to share in any recovery is not affected by the decision whether or not to seek appointment as a lead plaintiff, lead plaintiffs make important decisions which could affect the overall recovery for class members.

While Izard Nobel LLP has not filed a lawsuit against the defendants, to view a copy of the Complaint initiating the class action or for more information about the case, and your rights, visit: www.izardnobel.com/repros/, or contact Izard Nobel LLP toll-free: (800) 797-5499, or by e-mail: firm@izardnobel.com. For more information about class action cases in general, please visit our website: www.izardnobel.com.

Contact Information